InsiderSignalSign in

← Insider buys

SPRO

Spero Therapeutics, Inc. · Healthcare

Insiders sold $315K of Spero Therapeutics, Inc. in the last 12 months and bought none

$0Bought, 12 mo

$315KSold, 12 mo

$69.9MMarket cap

SPRO over the last year

No insider buys filed in this year

SPRO after insider buys

3 months after each buy, from the first price a copier could get.

−61.6%Average

−58.5 ptsVs S&P 500

0 of 13Higher

13 buys since 2017 with 3 months of prices.

Every filing

47 insider filings since 2017, newest first

Esther Rajavelu · Insider

$63K−2.0%May 6

Esther Rajavelu · Insider

$207K−8.0%Feb 9

Timothy Keutzer · COO

$44K−2.0%Feb 9

Esther Rajavelu · CFO, CBO

$53K−10.0%Nov 12

Sath Shukla · CEO and President

$43K−3.0%Aug 6

Timothy Keutzer · COO

$42K−5.0%Feb 5

Ankit Mahadevia · Director

$87K−8.0%Feb 5

Tamara L Joseph · General Counsel

$42K−5.0%Feb 5

Kamal Hamed · Chief Medical Officer

$38K−3.0%Feb 5

Sath Shukla · CEO and President

$108K−6.0%Feb 5

Kamal Hamed · Chief Medical Officer

$50K−6.0%Sep 15

Aquilo Capital Management, LLC · 10% owner

$4.3M−36.0%Sep 26

Aquilo Capital Management, LLC · 10% owner

$208K+1.0%Apr 28

Aquilo Capital Management, LLC · 10% owner

$439K+1.0%Mar 31

Aquilo Capital Management, LLC · 10% owner

Aquilo Capital Management, LLC · 10% owner

$427K+1.0%Mar 2

Aquilo Capital Management, LLC · 10% owner

Aquilo Capital Management, LLC · 10% owner

$1.4M+2.0%Feb 1

Aquilo Capital Management, LLC · 10% owner

$602K+1.0%Jan 20

Aquilo Capital Management, LLC · 10% owner

Aquilo Capital Management, LLC · 10% owner

$3.9M+5.0%Jan 3

Ankit Mahadevia · CEO and President

$117K−5.0%Dec 29

Aquilo Capital Management, LLC · 10% owner

$2.6M+3.0%Nov 2

Aquilo Capital Management, LLC · 10% owner

$2.5M+3.0%Oct 4

Aquilo Capital Management, LLC · 10% owner

$861K+1.0%Sep 15

Aquilo Capital Management, LLC · 10% owner

$458K+1.0%Sep 10

Aquilo Capital Management, LLC · 10% owner

$1.7M+1.0%Sep 1

Aquilo Capital Management, LLC · 10% owner

$616K+1.0%Aug 27

Aquilo Capital Management, LLC · 10% owner

$6.2M+10.0%Aug 24

Aquilo Capital Management, LLC · 10% owner

Aquilo Capital Management, LLC · 10% owner

$1.9M−3.0%Feb 4

Aquilo Capital Management, LLC · 10% owner

$5.0M−6.0%Dec 18

Cristina Larkin · COO

$228K−89.0%Dec 18

Aquilo Capital Management, LLC · 10% owner

$1.7M−3.0%Nov 10

Aquilo Capital Management, LLC · 10% owner

$2.5M−4.0%Nov 6

Ankit Mahadevia · CEO and President

$137K−13.0%Nov 5

Ankit Mahadevia · CEO and President

$207K−18.0%Oct 15

Ankit Mahadevia · CEO and President

$44K−4.0%Jul 9

Glaxosmithkline Plc · 10% owner

$1.0M+4.0%Jul 17

Cristina Larkin · COO

$70K−73.0%Jul 6

Joel Sendek · CFO

$35K−12.0%Jul 6

Ankit Mahadevia · Insider

$82K−7.0%Jul 6

Glaxosmithkline Plc · 10% owner

$6.0M+30.0%Nov 7

Jean Francois Formela · Director

$6.0M+22.0%Nov 7

Vikas Goyal · Director

$6.0M+30.0%Nov 7

Joel Sendek · CFO

$70K+25.0%Nov 7

Casper Breum · Director

$3.0M+24.0%Nov 7

About Spero Therapeutics, Inc.

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.